肿瘤浸润淋巴细胞对接受一线治疗的HER2阳性转移性乳腺癌的预后影响
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.
作者信息
Taurelli Salimbeni Beatrice, Giudici Fabiola, Pescia Carlo, Berton Giachetti Pier Paolo Maria, Scafetta Roberta, Zagami Paola, Marra Antonio, Trapani Dario, Esposito Angela, Scagnoli Simone, Cerbelli Bruna, Botticelli Andrea, Munzone Elisabetta, Fusco Nicola, Criscitiello Carmen, Curigliano Giuseppe
机构信息
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
出版信息
NPJ Breast Cancer. 2025 May 10;11(1):41. doi: 10.1038/s41523-025-00760-9.
Breast cancer (BC) is a leading cause of death among women, with approximately 30% HER2-positive (HER2+). Although HER2-targeted therapies have improved outcomes for patients with HER2+ metastatic breast cancer (mBC), clinical challenges and prognostic variability remain. Tumor-infiltrating lymphocytes (TILs) have emerged as prognostic and predictive biomarkers in various tumors, including BC, but their role in HER2+ mBC is poorly understood. This multicentric retrospective cohort study evaluated the prognostic significance of TILs in 110 patients with HER2+ mBC treated with pertuzumab, trastuzumab, and taxane-based chemotherapy at two Italian institutes from June 2013 to May 2024. TILs were assessed on metastatic or primary tumor samples. High TILs levels (>5%) were independently associated with longer PFS and OS. TILs levels were higher in primary tumours than in metastases (p = 0.009), with significant variation by metastatic site. These findings underscore the potential of TILs as prognostic biomarkers in HER2+ mBC, necessitating further prospective studies.
乳腺癌（BC）是女性死亡的主要原因之一，约30%为HER2阳性（HER2+）。尽管针对HER2的疗法改善了HER2+转移性乳腺癌（mBC）患者的预后，但临床挑战和预后变异性仍然存在。肿瘤浸润淋巴细胞（TILs）已成为包括BC在内的各种肿瘤的预后和预测生物标志物，但其在HER2+mBC中的作用尚不清楚。这项多中心回顾性队列研究评估了2013年6月至2024年5月期间在意大利两家机构接受帕妥珠单抗、曲妥珠单抗和紫杉类化疗的110例HER2+mBC患者中TILs的预后意义。在转移瘤或原发肿瘤样本上评估TILs。高TILs水平（>5%）与更长的无进展生存期（PFS）和总生存期（OS）独立相关。原发肿瘤中的TILs水平高于转移瘤（p=0.009），且因转移部位而异。这些发现强调了TILs作为HER2+mBC预后生物标志物的潜力，需要进一步的前瞻性研究。
Zotero 插件